Anterior pituitary function in patients with nonfunctioning pituitary adenoma: results of longitudinal follow-up.
Studies of anterior pituitary function in patients treated for nonfunctioning pituitary adenomas have been limited by their short duration. The purpose of the present study was to examine pituitary function longitudinally among three types of patients: those with complete tumor removal (group A); those with subtotal or partial adenomectomy (group B); and those in group B who underwent additional radiation therapy (group C). The subjects were 33 patients whose anterior pituitary function was evaluated by provocative tests such as insulin induced hypoglycemia, thyrotropin releasing hormone administration test and luteinizing hormone releasing hormone administration test. They underwent preoperative evaluation and postoperative reevaluations at 2 weeks, 3 months, 6 months and annually thereafter, for over 10 years. Anterior pituitary function was restored within a year after surgery, if at all. No additional function was restored after one year from treatment. In group A, no one developed impairment of anterior pituitary function after one year from surgery. In group B, however, new impairment was noted at intervals, due to tumor regrowth. In Group C, deficiencies developed after one year, irrespective of tumor regrowth. In conclusion, lifelong endocrinological follow-up is recommended for patients receiving postoperative irradiation, and for patients with potential for tumor regrowth. On the other hand, patients with total adenomectomy may be exempted from periodic endocrinological follow-up if they do not need postoperative hormonal replacement therapy.
Tominaga
A
A
Department of Neurosurgery, Hiroshima University School of Medicine, Japan.
Uozumi
T
T
Arita
K
K
Kurisu
K
K
Yano
T
T
Hirohata
T
T
D000236:Adenoma / Q000503:physiopathology / Q000532:radiotherapy / Q000601:surgery*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D000368:Aged; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D008137:Longitudinal Studies; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D010911:Pituitary Neoplasms / Q000503:physiopathology / Q000532:radiotherapy / Q000601:surgery*; D011184:Postoperative Period; D011388:Prolactin / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism
D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D013006:Growth Hormone